Skip to main content

Clinical Trial Search Results

A scientist pointing to an image of a DNA chain.

Clinical Trial Search Results

Showing 37-45 out of 310 results.
NCT03914625

A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)

Icon for trial | AALL1731 A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B

This study is currently enrolling.

The overall goal of Part I of this study is to collect information about your leukemia and your response to the first phase of treatment, called Induction. Part I of the study is necessary to determine if you will be eligible f ...

NCT05654922

A Phase 3, Open-Label, Randomized, Standard of Care- Controlled, Parallel Arm Study to Demonstrate Efficacy and Safety of ARINA-1 in the Prevention of Bronchiolitis Obliterans Syndrome Progression in Participants with Bilateral Lung Transplant

Icon for trial | RVN-001 A Phase 3, Open-Label, Randomized, Standard of Care- Controlled, Parallel Arm Study to Demonstrate Efficacy and Safety of ARINA-1 in the Prevention of Bronchiolitis Obliterans Syndrome Progression in Participants with Bilateral Lung Transplant

This study is currently enrolling.

The purpose of this research study is to see if the investigational drug, ARINA-1 when used with the investigational PARI eFlow nebulizer system, can stabilize or improve the lung function of participants who have had a bilater ...

NCT05757869

A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation

Icon for trial | 70033093AFL3002 A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation

This study is currently enrolling.

The purpose of this research study is to compare the effects of an experimental drug, milvexian, to the comparator drug, apixaban, to determine if it is safe and useful in reducing the risk of stroke and blood clots outside the ...

NCT05702034

A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack

Icon for trial | 70033093STR3001 A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Is

This study is currently enrolling.

The purpose of this study is to see if an experimental drug, called Milvexian in addition to standard of care, is safe and useful in reducing the risk of future ischemic stroke in subjects after ischemic stroke or transient isc ...

NCT04529772

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R CHOP) in Subjects ≤70 Years with Previously Untreated Non-Germinal Center Diffuse Large B Cell Lymphoma

Icon for trial | ACE-LY-312 (ESCALADE) A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R CHOP) in Subjects ≤70 Years with Previously Untreated Non-

This study is currently enrolling.

This study is being done to understand whether patients with a type of DLBCL known as non-germinal center diffuse large B-cell lymphoma (non-GCB DLBCL) will benefit from the addition of acalabrutinib to standard R-CHOP versus R ...

NCT05093634

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study: 5 Independent Sub-studies of Setmelanotide in Patients with POMC, PCSK1, LEPR, SRC1, SH2B1, and PCSK1 N221D Gene Defects in the Melanocortin-4 Receptor Pathway

Icon for trial | RM-493-035 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study: 5 Independent Sub-studies of Setmelanotide in Patients with POMC, PCSK1, LEPR, SRC1, SH2B1, and PCSK1 N221D Gene Defects in the Melanocortin-4 Receptor Pathway

This study is currently enrolling.

Appetite (feeling of hunger and feeling of being full after eating) and weight can be controlled by certain genes located in the brain. These genes are part of the Melanocortin-4-Receptor pathway (MC4R). Sometimes there is a ge ...

NCT04836390

A Phase II Pilot Study of Donor-Derived Ex-VivoExpanded Natural Killer Cell Infusions in Childrenand Young Adults with High-Risk Acute Myeloid Leukemia Receiving Myeloablative HLA Haploidentical Hematopoietic Cell Transplant: A Multicenter Pediatric Transplantation and Cellular Therapy Consortium (PTCTC) Study (EXCEL Trial) PTCTC CT2001.

Icon for trial | CT2001 A Phase II Pilot Study of Donor-Derived Ex-VivoExpanded Natural Killer Cell Infusions in Childrenand Young Adults with High-Risk Acute Myeloid Leukemia Receiving Myeloablative HLA Haploidentical Hematopoietic Cell Transplant: A Multicenter Pediatri

This study is currently enrolling.

Participants will be invited to join this study if they have a blood disease called acute myeloid leukemia (AML) and it has been decided that they need a transplant as part of their treatment plan. The purpose of this research ...